Dr. Reddy's and Nestlé Health Science Limited, a joint venture between Dr. Reddy’s Laboratories Ltd and Nestlé India Limited, has introduced Celevida GLP+. This scientifically formulated nutrition solution is designed to help patients in India maintain muscle mass and optimal nutrient levels while undergoing GLP-1/GIP therapy for Type 2 diabetes or obesity.

As GLP-1/GIP therapies gain widespread adoption for managing type 2 diabetes and obesity, improving patient access to advanced treatment, building an integrated ecosystem—beyond just medication—is becoming crucial.

M.V. Ramana, CEO, Global Generics at Dr. Reddy's Laboratories Limited and Director, Dr. Reddy's and Nestlé Health Science Limited said, “With Celevida GLP+, we aim to address this gap through a targeted, science-backed nutritional solution that complements pharmacological therapies and supports better overall patient outcomes in their everyday journey. As part of this commitment, we remain focused on advancing integrated, patient-centric solutions that enable more sustainable and holistic management of metabolic health.”

Celevida GLP+ offers high-performance nutrition with 48g of protein per 100g and 100% RDA of branched-chain amino acids (BCAAs) to support muscle health. This specialized formula also provides 27 essential nutrients, including key vitamins A, D, and calcium for comprehensive nutritional support, often used during GLP-1 therapy.

Clinically proven to support 24-hour blood glucose management and reduce HbA1c levels [6], this low-glycaemic index formulation [7] is ideal for long-term metabolic care.

Celevida GLP+ is available in 350g packs at pharmacies, retail stores, and top e-commerce platforms.